AbbVie is a global biopharmaceutical company that focuses on the research, development, and commercialization of advanced therapies to treat complex diseases across multiple therapeutic areas, including immunology, oncology, neuroscience, and virology. The company is known for its innovative biologics and pharmaceutical products aimed at addressing unmet medical needs, improving patient outcomes, and enhancing the quality of life for individuals suffering from chronic and acute health conditions. Through a combination of scientific expertise and strategic partnerships, AbbVie continuously strives to push the boundaries of medical science and expand its portfolio of leading-edge treatments. Read More
Thousand Oaks, CA – October 31, 2025 – Amgen (NASDAQ: AMGN), a leading biotechnology giant, has declared a quarterly dividend of $2.38 per share for the fourth quarter of 2025. This significant announcement, made well in advance of the payment date, underscores the company's robust financial health and unwavering commitment to
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Friday as we examine the latest happenings in today's session.
Shares of pharmaceutical company AbbVie (NYSE:ABBV) fell 3.9% in the afternoon session after the company reported third-quarter results that were overshadowed by a steep drop in profitability and a reduced earnings forecast for the full year. Although AbbVie's quarterly revenue of $15.78 billion and adjusted earnings per share (EPS) of $1.86 both surpassed Wall Street's estimates, investors focused on underlying weaknesses. The company's operating margin fell sharply to 12.1% from 26.5% a year ago, signaling rising costs were eroding profits. More significantly, AbbVie lowered its full-year adjusted EPS guidance to a midpoint of $10.63. This downward revision suggested to investors that the company's profitability challenges would persist, outweighing the positive top- and bottom-line beats for the quarter.
San Francisco, CA – October 31, 2025 – Artificial intelligence (AI) is ushering in a transformative era for the pharmaceutical industry, particularly in the often-overlooked yet critical domain of excipient development. These "inactive" ingredients, which constitute the bulk of most drug formulations, are now at the forefront of an AI-driven innovation wave. By leveraging advanced [...]
Stay informed about the performance of the S&P500 index in the middle of the day on Friday. Uncover the top gainers and losers in today's session for valuable insights.
The pharmaceutical industry is in the midst of a profound and rapid transformation, driven by the pervasive integration of Artificial Intelligence (AI). What was once a futuristic concept is, by late 2025, an established force, fundamentally reshaping drug development and operational workflows. This shift is not merely incremental but a comprehensive revolution, accelerating Research & [...]
Tech stocks edged higher Friday, rebounding from Thursday's 1.5% drop in the Nasdaq 100 as upbeat earnings from mega-cap giants kept the rally momentum alive.
Friday's session is showcasing interesting market movements in the S&P500 index, with notable gap up and gap down stocks. Stay updated with the gapping S&P500 stocks in today's session.
Pharmaceutical company AbbVie (NYSE:ABBV) announced better-than-expected revenue in Q3 CY2025, with sales up 9.1% year on year to $15.78 billion. Its non-GAAP profit of $1.86 per share was 4.2% above analysts’ consensus estimates.
When Wall Street turns bearish on a stock, it’s worth paying attention.
These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.
